Cellerant Therapeutics company logo

The profile is currenly unclaimed by the seller. All information is provided by CB Insights.



Debt - III | Alive

Total Raised


Last Raised

$6.55M | 6 yrs ago

About Cellerant Therapeutics

Cellerant Therapeutics is a clinical stage biotechnology company focused on the regulation of the hematopoietic (blood-forming) system. The Company is developing human stem cell and antibody therapies for oncology applications and blood-related disorders. Cellerant's lead product, CLT-008 is currently in two Phase 1 clinical trials in patients with hematological malignancies. The Company also has a Cancer Stem Cell (CSC) antibody discovery program focused on therapies for acute myeloid leukemia, multiple myeloma and myelodysplastic syndrome.

Cellerant Therapeutics Headquarter Location

1561 Industrial Road

San Carlos, California, 94070,

United States


Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Expert Collections containing Cellerant Therapeutics

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Cellerant Therapeutics is included in 3 Expert Collections, including Cancer.



4,784 items

Pharmaceutical and biotechnology companies with cancer therapy drug candidates.


Regenerative Medicine

1,818 items

Regenerative medicine refers to the process of activating, replacing, engineering or regenerating human genetic material, cells, tissues or organs to restore normal function. It also includes bioengineered tissues used for in vitro testing (e.g. organ-on-a-chip, organoids).


Biopharma Tech

838 items

Cellerant Therapeutics Patents

Cellerant Therapeutics has filed 25 patents.

The 3 most popular patent topics include:

  • Clusters of differentiation
  • Immunology
  • Transcription factors
patents chart

Application Date

Grant Date


Related Topics




Transcription factors, Immune system, Immunology, Clusters of differentiation, Experimental cancer drugs


Application Date


Grant Date



Related Topics

Transcription factors, Immune system, Immunology, Clusters of differentiation, Experimental cancer drugs



Latest Cellerant Therapeutics News

ONK Therapeutics Announces Three Exclusive Option License Agreements, Which Extend and Strengthen its Dual-Targeted NK Cell Therapy Pipeline

Dec 17, 2020

Three new exclusive option license agreements expand the depth and breadth of ONK’s pre-clinical pipeline A humanized scFv targeting CLEC12A licensed from Cellerant Therapeutics, creates a fourth pre-clinical program, ONKT104, for the treatment of acute myeloid leukemia (AML) A humanized scFv targeting a novel tumor-specific MUC1 glycopeptide epitopelicensed from Glycotope GmbH, strengthens pre-clinical program ONKT103, for solid tumors A CCR7 homing receptor licensed from the National Institute of Health (NIH), for use in the pre-clinical ONKT101 program, for relapsed/refractory B cell malignancies December 17, 2020 03:30 AM Eastern Standard Time GALWAY, Ireland, & SAN DIEGO, Calif.--( BUSINESS WIRE )--ONK Therapeutics Ltd, an innovative natural killer (NK) cell therapy company, today announced that it has secured three new exclusive option license agreements which strengthen its off-the-shelf, dual-targeted natural killer (NK) cell therapy platform and extend its pre-clinical pipeline to four programs across both hematological and solid tumors. The first option agreement, with Cellerant Therapeutics, gives exclusive rights to a humanized CLEC12A scFv binder. CLEC12A is strongly expressed by blasts in the majority of AML patients. The option to license has enabled ONK to expand its pre-clinical product portfolio, launching a fourth program (ONKT104). This dual-targeted approach combines the CLEC12A CAR with a TNF-related apoptosis-inducing ligand variant (TRAILv) targeting death receptor 4 (DR4). “While expressed on leukemic stem cells, CLEC12A is absent from normal hematopoietic stem cells and we thus expect that our dual-targeted NK cell therapy approach should enable safe targeting, with a reduced risk of prolonged aplasia in AML,” said Prof Michael O’Dwyer MD, ONK Therapeutics’ co-founder, and CSO. The second agreement in-licenses a humanized, tumor-specific antibody targeting an aberrantly glycosylated tumor-associated form of MUC1 (TA-MUC1) from Glycotope GmbH. Multiple solid tumor types express the mucin MUC1, including non-small cell lung cancer, breast cancer, and ovarian cancer. This antibody will be integrated into ONK’s pre-clinical program ONKT103, for solid tumors. Non-selective targeting of MUC1 could be problematic since the target is also expressed by healthy tissues, but O’Dwyer explains how ONK’s dual-targeted approach can be used to address this. “We have designed a CAR tailored to the glycosylation pattern distinct to tumor-associated MUC1 with specific recognition of the carbohydrate antigens Tn and T on MUC1, the expression of which is restricted to cancer cells. Glycotope has identified the glycosylation pattern as a way to unlock the potential of TA-MUC1 as a solid tumor target. ONK is thus set to bring the natural benefits of NK cells over T cells to bear on TA-MUC1, in a tumor-specific fashion, while also further boosting efficacy and countering resistance through the use of our TRAIL variant targeting DR5,” he said. ONK’s unique platform approach combines the expression of a chimeric antigen receptor (CAR) and a high affinity, membrane-bound TRAILv. The incorporation of these two humanized scFvs has the potential to minimize the risk of immunogenicity in the allogeneic setting. ONK is also exploring several innovative strategies to improve the homing of NK cells. This is an important consideration as ex-vivo expansion can lead to changes in chemokine receptor expression. Through this new license agreement with the NIH, ONK plans to enforce the expression of CCR7, which is downregulated on NK cell expansion. This may improve the homing of NK cells to lymph nodes and is expected to be particularly useful for ONK’s off-the-shelf CD19 program targeting B cell lymphoma, ONKT101, which is partnered with Avectas. ONK is making rapid progress since it announced its most recent financing in October. Chris Nowers, ex Kite Pharma Head of Europe, who joined at that time as Chief Executive Officer, said: “The recent American Society of Hematology meeting highlighted the NK cell therapy area as offering great hope as the next generation of advanced cell therapies. We believe our best-in-class off-the-shelf, dual-targeted NK cell therapy platform has the potential to improve performance and overcome some of the shortcomings seen with earlier approaches. These new licensing activities strengthen and expand our programs and illustrate our ambition and strategy to become a leader in this exciting field.” The company recently expanded its operations into the USA, moving into JLABS @ San Diego, Johnson & Johnson Innovation’s flagship facility, at the heart of San Diego’s precision medicine and cell therapy cluster. This represents a second facility that complements its main R&D team and operations in Galway, Ireland. The company’s recruitment drive across both facilities has been rapid and the company continues to expand its capability in key areas, including NK cell biology, construct design, gene editing, and process development. -Ends- ONK Therapeutics Ltd is an innovative cell therapy company dedicated to developing the next generation of ‘off-the-shelf’, dual-targeted NK cell therapies targeting solid and hematological cancers. The company was founded in 2015, by Prof. O’Dwyer MD, of NUI Galway, an expert in translational multiple myeloma research, the tumor microenvironment, and exploitation of NK cells as cellular immunotherapy. Its core proprietary platform is based on a dual-targeted NK cell expressing both a chimeric antigen receptor (CAR) targeting a known tumor antigen and a TNF-related apoptosis-inducing ligand variant (TRAILv) targeting the death receptor pathway (i.e. DR4 or DR5). This unique approach has the potential to enhance efficacy by addressing both intrinsic (e.g. CAR engagement of a tumor-specific antigen) and extrinsic (e.g. signaling through the death receptor pathway) apoptotic pathways and to reduce the susceptibility to possible target antigen escape through the engagement of tumor antigen-independent TRAILv. Its pre-clinical pipeline comprises four programs; The lead program, ONKT101, is a dual-targeted NK cell therapy incorporating a CD19 CAR and TRAILv targeting DR5, intended for the treatment of relapsed/refractory B cell malignancies. This program is partnered with Avectas, with the company having responsibility for development to Phase 1 ONKT102 combines an optimized affinity CD38 CAR and a TRAILv targeting DR5, intended for the treatment of patients with relapsed/refractory multiple myeloma ONKT103 combines a TA-MUC1 CAR with a TRAILv targeting DR5, for the treatment of solid tumors ONKT104 combines a CLEC12A CAR with a TRAILv targeting DR4, for the treatment of AML In addition to the unique dual-targeted NK cell therapy platform, the company has a strong research focus on strategies to enhance homing and persistence, and overcome exhaustion, including the exploration of proprietary gene edits, such as the deletion of checkpoint inhibitory receptors in NK cells. ONK Therapeutics is headquartered in the med-tech hub of Galway, Ireland, with a wholly-owned US subsidiary, ONK Therapeutics, Inc. based at JLabs @ San Diego. Shareholders include Acorn Bioventures, ALSHC (principally Seamus Mulligan), and Enterprise Ireland.

  • Where is Cellerant Therapeutics's headquarters?

    Cellerant Therapeutics's headquarters is located at 1561 Industrial Road, San Carlos.

  • What is Cellerant Therapeutics's latest funding round?

    Cellerant Therapeutics's latest funding round is Debt - III.

  • How much did Cellerant Therapeutics raise?

    Cellerant Therapeutics raised a total of $64.54M.

  • Who are the investors of Cellerant Therapeutics?

    Investors of Cellerant Therapeutics include Allen & Company, Camelot Venture Group, GBR Investments, Sears Capital Management, Sagamore BioVentures and 16 more.

  • Who are Cellerant Therapeutics's competitors?

    Competitors of Cellerant Therapeutics include Longevica, Alethia BioTherapeutics, Endocyte, Threshold Pharmaceuticals, Celator Pharmaceuticals, RhinoCyte, Mirna Therapeutics, ACT Biotech, ERYtech Pharma, NKT Therapeutics and 12 more.

You May Also Like

American Stem Cell

ASC is a privately held biotechnology company dedicated to the development and commercialization of enabling technologies to enhance and expand the therapeutic potential of stem cell therapies. The key technology platforms (ASC-101 and ASC-201) are designed to improve the homing and engraftment of stem cells to target organs and increase their therapeutic potential for cancer patients. Additionally, these platforms have the potential to enhance stem cell treatment of inflammation from chemotherapy/radiation, solid tumors, autoimmune diseases, and ischemic diseases including myocardial infarction and stroke. ASC has strategic partnerships with medical research institutions including the University of Texas M.D. Anderson Cancer Center, the Oklahoma Medical Research Foundation, University of California, the Burnham Institute, Indiana University, Rush Presbyterian and VidaCord Technologia Biomedica.

Enox Biopharma

Enox Biopharma is a biotechnology company that developed a drug eluting technology suitable for treatment of acute and antibiotic resistant ear infection in children.

Amrita Therapeutics

Amrita Therapeutics develops drugs that combat public health threats of the 21st century with fewer side-effects and at an cost. Amrita Therapeutics therapies and cures will treat cervical cancer, CNS disorders, HIV/AIDS, malaria and/or tuberculosis by designing the products of bacteria to defend the human body against more than one disease simultaneously, utilizing or interfering in multiple pathways or mechanisms.

Stem Cells Bank

Stem Cells Bank Biotechnological Company engaged in development of autovaccines for treating oncological diseases and tuberculosis, produced on the basis of autologous dendritic cells (cells extracted from the organism of the very patient to be given the vaccine). In the framework of thus project it is planned to develop and launch a vaccine for treating oncological diseases and tuberculosis, produced on the basis of cells extracted from the organism of the very patient to be given the vaccine.

Biosceptre International

Biosceptre has identified a pan-cancer target, present in many cancer types, and importantly not found in healthy tissue. Early research and initial evidence suggest that drugs directed at the nf-P2X7 target have the potential to redefine cancer therapy. The Company has raised AUD33m and will be raising further capital through both existing and new investors. Biosceptre has a rigorous, international patent portfolio extending to 2032, providing broad protection of the target and specific protection of antibody products. The Company is developing therapeutics and diagnostics to bind nf-P2X7, with the core of product development in topical and systemic cancer drugs. Biosceptreis also developing an immuno-oncology vaccine, through an existing collaboration, and is in discussions with developmental partners to develop diagnostic and imaging technologies to detect and monitor cancer. Biosceptre is supported by a world-class scientific advisory board, the members of which have been central in the development of numerous, highly successful, biotechnology companies and products. The Company has the team, capital, and plan to create substantial value from this unique, patent-protected, technology. The business is headquartered in Cambridge, UK with additional research facilities in Sydney, Australia.

Aliva Biopharmaceuticals

Aliva Biopharmaceuticals is a company that received a SBIR Phase I grant for a project entitled: Humanized Mouse Ig system employing BAC. Their research project aims to introduce the entire human immunoglobulin locus into the mouse in order to enable the subsequent production of completely humanized monoclonal antibodies from hybridomas. Monoclonal antibodies against cell surface proteins are currently being used for a variety of clinical indications, including cancer and autoimmunity. Their binding avidity and specificity make them one of the most important modes of therapy for the treatment of a variety of diseases where specific targeting is required. The current technology is based on a system where only 80% of the immunoglobulin locus has been humanized. Replacement of the remaining mouse genes with the human ones will improve the quality and diversity of the antibodies produced and as such, will be an important contribution to this important therapeutic modality.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.